Neurocrine Biosciences
NBIX
NBIX
403 hedge funds and large institutions have $8.59B invested in Neurocrine Biosciences in 2020 Q4 according to their latest regulatory filings, with 63 funds opening new positions, 145 increasing their positions, 150 reducing their positions, and 73 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
403
Holders Change
-14
Holders Change %
-3.36%
% of All Funds
7.15%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.09%
New
63
Increased
145
Reduced
150
Closed
73
Calls
$39.8M
Puts
$116M
Net Calls
-$76.5M
Net Calls Change
+$18.6M
Top Buyers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$250M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$80.1M |
| 3 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$38.3M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$35.1M |
| 5 |
PA
Perceptive Advisors
New York
|
+$33.6M |
Top Sellers
| 1 |
Capital International Investors
Los Angeles,
California
|
-$82.7M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$68.9M |
| 3 |
HM
HealthCor Management
New York
|
-$67.2M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$62.3M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$61.3M |
